Background
Vaccine efficacy reflects the proportionate reduction in disease incidence between unvaccinated and vaccinated individuals . While vaccines are typically licensed on the basis of demonstrated efficacy, the ultimate goal of vaccination is to achieve a significant public health impact in addition to the prevention of infection in an individual. In this respect, there is a need to provide a broader perspective that encompasses the capacity of a vaccination program to reduce microbial transmission, avert disease, disability and premature deaths, and to lessen the pressure on health system and to reduce health inequities between populations. These issues are particularly relevant for some of the newer vaccines (e.g., rotavirus, dengue, and malaria vaccines) that demonstrate lower efficacy in high burden settings than traditional vaccines, but nevertheless could have a substantial overall public health impact in these settings.
Data on a vaccine's public health benefit are often not available or may be incomplete . As a consequence, decision-makers and target populations may underestimate the justification for vaccine use, leading to delays in public immunization program introduction, and ongoing preventable disease burden. The slow introduction of rotavirus vaccine in developing countries despite evidence of enormous decreases in severe disease and hospital utilization is one example . 
